These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. American Society of Clinical Oncology guidance statement: the cost of cancer care. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, American Society of Clinical Oncology. J Clin Oncol; 2009 Aug 10; 27(23):3868-74. PubMed ID: 19581533 [Abstract] [Full Text] [Related]
24. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. Pinheiro Edos S, Antunes OA, Fortunak JM. Antiviral Res; 2008 Sep 10; 79(3):143-65. PubMed ID: 18571246 [Abstract] [Full Text] [Related]
25. Financing of HIV/AIDS programme scale-up in low-income and middle-income countries, 2009-31. Hecht R, Stover J, Bollinger L, Muhib F, Case K, de Ferranti D. Lancet; 2010 Oct 09; 376(9748):1254-60. PubMed ID: 20934597 [Abstract] [Full Text] [Related]
26. [Ten years of commitment to persons living with HIV-AIDS: evaluation of the management in three ambulatory treatment centers of the French Red Cross in Africa]. Mouala C, Madec Y, Adam G, Courpotin C, Fikouma V, Gentilini M, Ould Mohamedoune A, Nzounza P, Schaer E, Simon B, Mattei JF. Sante; 2008 Oct 09; 18(2):89-95. PubMed ID: 19188132 [Abstract] [Full Text] [Related]
28. The challenges to scaling up antiretroviral therapy in Papua New Guinea. Raynes P, Maibani G. P N G Med J; 2006 Oct 09; 49(1-2):32-42. PubMed ID: 18396610 [Abstract] [Full Text] [Related]
29. Migration, mental health and costs consequences in Romania. Miclutia I, Junjan V, Popescu CA, Tigan S. J Ment Health Policy Econ; 2007 Mar 09; 10(1):43-50. PubMed ID: 17417046 [Abstract] [Full Text] [Related]
31. Patient preferences for depression treatment programs and willingness to pay for treatment. Morey E, Thacher JA, Craighead WE. J Ment Health Policy Econ; 2007 Jun 09; 10(2):73-85. PubMed ID: 17603148 [Abstract] [Full Text] [Related]
32. [Development of antituberculous drugs: current status and future prospects]. Tomioka H, Namba K. Kekkaku; 2006 Dec 09; 81(12):753-74. PubMed ID: 17240921 [Abstract] [Full Text] [Related]
35. Bridging the resource gap: improving value for money in HIV/AIDS treatment. Soni A, Gupta R. Health Aff (Millwood); 2009 Dec 09; 28(6):1617-28. PubMed ID: 19887403 [Abstract] [Full Text] [Related]
36. Estimating the cost of epilepsy in Europe: a review with economic modeling. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Epilepsia; 2007 Dec 09; 48(12):2224-33. PubMed ID: 18088267 [Abstract] [Full Text] [Related]
38. Income and employment of people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders. Conover CJ, Arno P, Weaver M, Ang A, Ettner SL. J Ment Health Policy Econ; 2006 Jun 09; 9(2):71-86. PubMed ID: 17007485 [Abstract] [Full Text] [Related]
39. Rationing antiretroviral therapy for HIV/AIDS in Africa: choices and consequences. Rosen S, Sanne I, Collier A, Simon JL. PLoS Med; 2005 Nov 09; 2(11):e303. PubMed ID: 16159308 [Abstract] [Full Text] [Related]